Apnimed to Restate Financial Statements Over $85.4 Million Gain Misclassification

• Apnimed will restate second-quarter and first-half 2026 financial statements following misclassification of an $85.4 million disposal gain.
• The gain on its Shionogi-Apnimed Sleep Science stake sale should have been classified as discontinued operations rather than continuing operations.
• On November 13, 2026, the audit committee determined the affected statements should no longer be relied upon; an amended filing is planned that day.
• The correction does not affect total net income, earnings per share or cash flows.
• Previously disclosed material weaknesses left disclosure controls ineffective; management is assessing the restatement's implications for internal controls.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apnimed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-460864), on November 13, 2026, and is solely responsible for the information contained therein.